ProShares Ultra NASDAQ Biotechnology
38 hedge funds and large institutions have $23.3M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 8 closing their positions.
0.11% more ownership
Funds ownership: 6.63% → 6.74% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $24.1M → $23.3M (-$762K)
7% less funds holding
Funds holding: 41 → 38 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
62% less call options, than puts
Call options by funds: $8.07M | Put options by funds: $21.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.65M |
| 2 |
SAM
Stansberry Asset Management
Westlake,
Texas
|
+$818K |
| 3 |
VF
Virtu Financial
New York
|
+$723K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$680K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$574K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
-$5.11M |
| 2 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$551K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$423K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$316K |
| 5 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
-$260K |
BIB Hedge Fund Activity: Q2 2018 in Review
38 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2018, worth a combined $23.3M — down 3.2% from $24.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BIB and 5 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 5 added.
The largest buyer was Jane Street, opening a new position worth an estimated $1.65M. The largest seller was Opus Point Partners Management, cutting an estimated $5.11M.
- 38 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2018, down from 41 in Q1 2018.
- Funds reported $23.3M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2018, down 3.2% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2018 and 8 closed out, a net change of -3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2018 was Jane Street, an estimated $1.65M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2018 was Opus Point Partners Management, an estimated $5.11M sold.
Based on aggregated 13F filings for Q2 2018.